SII, Department of Biotechnology to launch India's first qHPV vaccine against cervical cancer tomorrow

"It is very effective and prevents cervical cancer because, 85 percent to 90 percent cases, cervical cancer is because of this particular virus and this vaccine is against those viruses," Dr N K Arora

Published On 2022-08-31 09:22 GMT   |   Update On 2022-08-31 09:22 GMT
Advertisement

New Delhi: The Serum Institute of India (SII) and the Department of Biotechnology(DBT) are set to launch India's first indigenously developed Quadrivalent Human Papillomavirus vaccine (qHPV) against Cervical Cancer on September 1, official sources told ANI.

The most awaited vaccine will be launched by the Union Minister of State (Independent Charge) Science & Technology Jitendra Singh on Thursday.
Advertisement
According to Dr N K Arora, Chairperson of the COVID working group, National Technical Advisory Group on Immunisation (NTAGI) said it is an exciting experience to launch a made-in-India vaccine.

Cervical cancer develops in a woman's cervix (the entrance to the uterus from the vagina).

Almost all cervical cancer cases (99%) are linked to infection with high-risk human papillomaviruses (HPV), an extremely common virus transmitted through sexual contact.

"It is very exciting and I must say it makes us very happy that our daughters and granddaughters will now be able to get this much-awaited vaccine."
"In fact, this is one of the last major vaccines to be introduced. In fact, this is one of the last vaccines that will be launched in the programme. Now, Indian vaccines will be available and we hope that it will be launched in the National Immunisation programme for 9-14-year-old girls," he added.
"It is very effective and prevents cervical cancer because, 85 percent to 90 percent cases, cervical cancer is because of this particular virus and this vaccine is against those viruses. So, if we give it to our young children and daughters, they are protected from the infection and consequently probably 30 years later, cancer does not occur," Dr Arora further explained.
"There was a shortage in the global market. Now Indian vaccine has come. So, we will be able to take care of our requirements within our made-in-India vaccine," he said.
Tags:    
Article Source : ANI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News